Boston Scientific was the worst performer in the S&P 500 Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter.

The Investment Committee detail their latest portfolio moves. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC ...

Securities Fraud Investigation Into Boston Scientific Corporation (BSX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm ...

Boston Scientific’s electrophysiology business stumbled as competition from Medtronic, Johnson & Johnson, Abbott, and others in the pulsed-field ablation (PFA) space intensified. Marie Thibault, a ...

Few analysts foresaw the disappointing results and profit forecast that sent Boston Scientific Corp.’s shares plummeting nearly 20% this week. Even fewer have given up on their bullish calls since. It ...

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024 at Alumni Stadium in ...

In October, Boston Scientific announced plans to dive into the peripheral nerve stimulation space through the acquisition of medtech company Nalu Medical. Boston Scientific has been a Nalu investor ...

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was ...

The stock slid 18% on softer EP sales and initial 2026 targets, leaving investors focused on March 28 CHAMPION-AF results and China-driven growth. Worries centered on EP, where Q4 revenue was $890 ...

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...